Summit Securities Group LLC Sells 21,563 Shares of Merck & Co., Inc. $MRK

Summit Securities Group LLC lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 72.4% in the first quarter, Holdings Channel.com reports. The fund owned 8,238 shares of the company’s stock after selling 21,563 shares during the quarter. Summit Securities Group LLC’s holdings in Merck & Co., Inc. were worth $991,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of MRK. Norges Bank bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $3,997,933,000. Wellington Management Group LLP grew its holdings in shares of Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the last quarter. Cardano Risk Management B.V. bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $1,012,530,000. Jennison Associates LLC purchased a new position in Merck & Co., Inc. in the 4th quarter worth about $585,192,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock worth $1,973,983,000 after buying an additional 5,152,069 shares during the period. Institutional investors own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s KEYTRUDA franchise got a boost from recent U.S. and EU approvals in breast and bladder cancer, expanding its use in hard-to-treat tumors and strengthening the company’s oncology growth story. Article Title
• Positive Sentiment: Merck also reached a new access agreement for its HIV treatment, IDVYNSO, which could modestly improve market access and commercial momentum for the product. Article Title
• Positive Sentiment: Several analysts remain constructive on Merck, including recent price-target increases from RBC and Wells Fargo, reflecting confidence in the company’s pipeline and KEYTRUDA-driven earnings power. Article Title
• Neutral Sentiment: Merck has been attracting elevated investor attention, but the related coverage is more about monitoring the stock’s setup than a new business catalyst. Article Title
• Neutral Sentiment: A market report on Southeast Asia oncology drug access listed Merck among peer companies, highlighting the broader opportunity for cancer therapy access but not pointing to a company-specific development. Article Title
• Negative Sentiment: Morgan Stanley trimmed its price target to $113 and kept an equal-weight rating, signaling limited near-term upside from current levels and reinforcing valuation caution. Article Title

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MRK. Wells Fargo & Company lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Scotiabank boosted their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $132.72.

Merck & Co., Inc. Stock Down 0.7%

Shares of Merck & Co., Inc. stock opened at $125.17 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $130.29. The firm’s 50-day moving average is $118.57 and its two-hundred day moving average is $116.23. The stock has a market cap of $309.14 billion, a price-to-earnings ratio of 35.26, a PEG ratio of 2.69 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the previous year, the business posted $2.22 EPS. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 5.19 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.